Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 760 participants.

Also called NCT04667143

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 760 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04667143
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04667143. Randomized; quadruple masking; primary purpose treatment. Start 2021-01 (anticipated); primary completion 2022-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
Condition
Diabetes Mellitus, Type II
Intervention (Drug)
Retagliptin, Henagliflozein, metformin XR
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04667143
Content hash
f2ed0ff42f8a1d9ad368a4da10eee5214ff71b4f14faeff6ef222887c95b490e